Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction

31 Jan 2025

Abstract excerpt

Myelomatous bone disease is a complication characterized by lytic bone lesions, reduced bone formation, bone pain, and increased fracture risk. Understanding these underlying mechanisms is crucial for developing effective therapeutic approaches. Here we show the role of enhancer of zeste homolog 2 (EZH2) in bone lesions induced by myeloma cells. Our research reveals that cytokines produced by myeloma-associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39885217
DOI: 10.1038/s41467-025-56506-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destructionPMID 39885217Read ↗

Epigenetic‐Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone DiseaseSemantic proximity Read ↗

Reprogrammed marrow adipocytes contribute to myeloma-induced bone diseaseSemantic proximity Read ↗

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast DifferentiationSemantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular BackgroundSemantic proximity Read ↗

Osteoblast suppression in multiple myeloma bone diseaseSemantic proximity Read ↗

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic targetSemantic proximity Read ↗

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.Semantic proximity Read ↗

Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease.Semantic proximity Read ↗

Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaSemantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.